0
0
0
0
1
2
3
$0
Is Moderna solid or fragile? The Finex Financial Health Scanner reads MRNA's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $1.9B |
|---|---|
| Net income | -$2.8B |
| Operating margin | -158.1% |
| Net margin | -145.2% |
| Cash and investments | $5.8B |
| Total debt | $610.0M |
| Free cash flow | $299.2M |
| Revenue growth (1 year) | -39.9% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.